CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

Nature Medicine

Volumn 5, Issue 5, 1999, Pages 548-553

  French, Ruth R ^a   Chan, H T Claude ^a   Tutt, Alison L ^a   Glennie, Martin J ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNOLOGY;

EID: 0032896709     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/8426     Document Type: Article

References (41)

1. Grewal, I.S. & Flavell, R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16, 111-135 (1998).
2. Noelle, R.J., Ledbetter, J.A. & Aruffo, A. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation, Immunol Today 13, 431-433 (1992).
3. Soong, L. et al. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonesis infection. Immunity 4, 263-273 (1996).
4. Campbell, K.A. et al. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 4, 283-289 (1996).
5. Kamanaka, M. et al. Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. Immunity 4, 275-281 (1996).
6. Stout R.D. et al. Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J. Immunol. 156, 8-11 (1996).
7. vanKooten, C. & Banchereau, J. Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol. 9, 330-337 (1997)
8. Ridge, J.P., Di Rosa, F. & Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474-478 (1998).
9. Bennett, S.R.M. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480 (1998).
10. Schoenberger, S.P. et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
11. Ferlin, W.G. et al. The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb. Eur. J. Immunol. 28, 525-531 (1998).
12. Dullforce, P., Sutton, D.C. & Heath, A.W. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies. Nature Med. 4, 88-91 (1998)
13. Dilloo, D. et al. CD40 ligand induces and antileukemia immune response in vivo. Blood 90, 1927-1933 (1997)
14. Schultze, J.L. et al. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 89, 3806-3816 (1997)
15. Schultze J.L. et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. 100, 2757-2765 (1997)
16. Kato, K., Cantwell, M.J., Sharma, S. & Kipps, T.J. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J. Clin. Invest. 101, 1133-1141 (1998)
17. Cardoso, A.A. et al. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 90, 549-561 (1997)
18. Tutt, A.L. et al. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol. 161, 3176-3185 (1998)
19. Hasbold, J. et al. Properties of mouse CD40: cellular distribution of CD40 and B cell activation by monoclonal anti-mouse CD40 antibodies. Eur. J. Immunol. 24, 1835-1845 (1994).
20. Rolink, A., Melchers, F. & Andersson, J. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 5, 319-330 (1996).
21. von Herrath, M.G. et al. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 70, 1072-1079 (1996)
22. + T cells. J. Exp. Med. 184, 863-871 (1996)
23. 1. J. Immunol. 138, 628-634 (1987)
24. Hurwitz, A. et al. CTLA-4 blockage synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA 95, 10067-10071 (1998)
25. Kurts, C. et al. Major histocompatibility complex class I-resticted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med. 188, 409-414 (1998)
26. Albert, A.L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89 (1998).
27. Pistoia, V. Production of cytokines by human B cells in health and disease. Immunol. Today 18, 343-350 (1997)
28. Khanna, R. et al. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J. Immunol. 159, 5782-5785 (1997)
29. Bevan M.J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143, 1283-1288 (1976).
30. Huang, A.Y. et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumour antigens. Science 264, 961-964 (1994)
31. + T cell help. J. Exp. Med. 186, 65-70 (1997).
32. 5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188, 1359-1368 (1998).
33. Rathmell, J.C. et al. Expansion or elimination of B cells in vivo: dual roles for CD40 and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 87,319-329 (1996).
34. Funakoshi, S. et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83, 2787-2794 (1994)
35. Wiley, J.A., Gaha, R. & Harmsen, A.G. Exogenous CD40 ligand induces a pulmonary inflammation response. J. Immunol. 158, 2932-2938 (1997)
36. Roskrow, M., Suzuki, N. & Brenner, M.K. Immunisation with peptide-pulsed dendritic cells stimulated with CD40 ligand protects leukemia but induces autoimmune disease. Blood 90 (S1), 2601 (1997).
37. Boon, T. et al. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365 (1994)
38. Cobbold, S.P., Martin, G. & Waldmann, H. The induction of skingraft tolerance in MHC-mismatched or primed recipients: primed T-cells can be tolerized in the periphery with CD4 and CD8 antibodies. Eur. J. Immunol. 20, 2747-2755 (1990)
39. 1 act primarily with heavy chain determinants. Hybridoma 10, 219-000 (1991).
40. 2 antibody. J. Immunol. 155, 2960-2971 (1995).
41. Honeychurch, J., Cruise, A., Tutt, A.L. & Glennie. M.J. Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome. Cancer Immunol. Immunother. 45, 171-174 (1997).